Pappas Capital

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

82VS is our affiliated venture studio that pairs Alloy’s platforms and services with a team of company creation experts to efficiently launch new asset-centric companies. Alloy works with exceptional founders, entrepreneurs- and executives-in-residence, and biotech and pharma partners to develop new medicines by efficiently leveraging the capabilities of the Alloy ecosystem at large. The 82VS name comes from the atomic number for lead, 82. To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work. We Partner We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest. We Build We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed. We Industrialize We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science. Our People We come from pharma, biotech, academia, and venture capital backgrounds. Our EIRs can pursue their scientific ideas with full operational support and can repeatedly harness the 82VS infrastructure to create more value. We launch new companies and support strategic investments Collectively the companies supported out of 82VS are pursuing next generation innovative treatments for cancer, neurodegeneration, autoimmune disease, hereditary blindness, and more. Our investments in next-generation manufacturing companies help our ecosystem of partners advance more quickly to the clinic. We create, in-license, and co-develop pre-competitive enabling technology platforms that help the entire drug discovery community move faster. We value the work of inventors, ensuring your work lands with maximum impact. There is nothing more frustrating to a scientist or engineer than to see their life’s work trapped inside one company and only able to be accessed and improved by a single team. Alloy’s mission is to unlock the potential of pre-competitive technologies by taking a very long view of investing in platform development and helping our partners and venture studios utilize these technologies as aggressively as possible. Generally, platform technology continues to be improved over time and with greater use and engagement from the ecosystem. It’s exciting to think that the technologies we invent today will be supported, improved and available to our ecosystem today and long into the future. Alloy reinvests 100% of our revenue back into innovation and access to innovation while sharing the value with the innovators themselves.

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

K2HV’s investment professionals bring together substantial experience across multiple verticals in healthcare finance and operations, as well as considerable scientific knowledge. Our diverse backgrounds and experience give us a deep understanding of the needs of innovative healthcare companies throughout their lifecycles, and underpin our innovative and creative approach to investing. Our leadership team has committed more than $4 billion to over 100 private and public companies in the life sciences and healthcare industries. High Impact Investments, Long-Term ViewUniquely flexible, permanent capital structure enables us to provide long-term financing solutions and meet the evolving capital needs of growing companies Broad investment mandate allows us to be creative with financing structures Primary focus on customized debt financings, but able to invest in equity as well

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund focusing on innovation and value investment with deep insight and experience on Asia markets. We are part of the Trinity Innovation Fund group, founded in 2018, managing multiple VC funds in the region. We are an experienced team led by industrial veterans who have managed multiple VC funds and invested over dozens of biotech companies. Our StrengthAccess to China market through synergy with TIF: Two organizations, One Team Multi-dimensional value-added post investment to enhance possibility of success and returns Clear investment thesis: In Asia, for Global; Leverage regional synergy and realize future value Best-in-class team in biomed investment with strong track record Our Focus TIBS seeks to invest and build great companies that emerging biotechnology leads to innovative therapeutics to address global unmet medical needs. We focus on incubating and growing potential early-stage biotech start-ups with breakthrough platform technology, differentiated scientific merit and commercial value. Our Core CompetencyValue Discovery: Select investment projects based on precise judgements from in-depth research Project Incubation: Incubate cutting-edge science or outstanding entrepreneurs with innovative approaches. Unique incubation strategy: project management by investment team to increase the asset value; management team recruitment to maximize the equity value and capital efficiency Help entrepreneurs to grow rapidly with proprietary foresight, industry understanding and resources